Tremelimumab, on the other hand, rapidly restores effector and memory CD4 + and CD8 + T-cell pools and T-cell receptor (TCR)-dependent T-cell proliferation in patients with advanced melanoma combined with severe lymphopenia [29, 30]. Here, CD8A is linked to melanoma.